This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Threshold Drug Delays Pancreatic Cancer

Stocks in this article: THLDCELGINFICLVS

Updated with new stock price.

SOUTH SAN FRANCISCO, Calif. ( TheStreet) -- Treatment with Threshold Pharmaceuticals' (THLD) TH-302 helped patients with advanced pancreatic cancer extended by two months the time before their disease worsened, according to results of a phase II study released Monday.

Shares of Threshold were up 65% to $5.82 in Tuesday trading.

Threshold is developing TH-302 in a partnership signed recently with the German pharmaceutical company Merck KGaA. A phase III study of TH-302 in advanced soft-tissue sarcoma is underway.

In the phase II study announced Monday, 214 patients with first-line advanced pancreatic cancer were randomized to treatment with either a low or high dose of TH-302 plus the gemcitabine or gemcitabine alone.

Patients in the two TH-302 arms of the study went 5.6 months before their disease worsened compared to 3.6 months for patients treated with gemcitabine alone -- or a two-month difference in progression-free survival favoring TH-302, Threshold reported.

Stated differently, treatment with TH-302 plus gemcitabine reduced the risk of pancreatic cancer worsening by 39% compared to gemcitabine alone. This result -- the primary endpoint of the phase II study -- was statistically significant. Patients treated with the high dose of TH-302 reported greater efficacy than those in in the low-dose arm, Threshold said, without providing details.

Significant tumor shrinkage was reported by 22% of patients treated with TH-302 plus gemcitabine compared to 12% for patients treated with gemcitabine alone.

Gemcitabine has long been used by itself to treat pancreatic cancer but efforts to add other drugs in combination have largely failed to demonstrate any significant benefit for patients. The one notable exception is the combination of Eli Lilly's (LLY) Tarceva plus gemcitabine.

Last year, a triple combination of chemotherapy agents -- gemcitabine, oxaliplatin and irinotecan known as FOLFIRINOX -- demonstrated overall survival in pancreatic cancer of 11.1 months compared to 6.8 months for gemcitabine alone and a progression-free survival benefit of 6.4 months vs. 3.3 months. However, the FOLFIRINOX survival benefit came at the cost of significant and serious side effects for patients.

Threshold said the TH-302-gemcitabine combination was well tolerated with chief side effects being skin and mucosal toxicities. Further details were withheld for presentation at a future medical meeting.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,390.52 +195.10 1.13%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs